• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复发性钙结石女性的骨骼和代谢标志物

Bone and metabolic markers in women with recurrent calcium stones.

作者信息

Arrabal-Polo Miguel Angel, Arrabal-Martin Miguel, Arias-Santiago Salvador

机构信息

Department of Urology, San Cecilio University Hospital, Granada, Spain.

出版信息

Korean J Urol. 2013 Mar;54(3):177-82. doi: 10.4111/kju.2013.54.3.177. Epub 2013 Mar 15.

DOI:10.4111/kju.2013.54.3.177
PMID:23526577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3604571/
Abstract

PURPOSE

The target of our work was to study several biochemical parameters in phospho-calcic and bone metabolism in blood and urine and the bone mineral density of women with recurrent calcium nephrolithiasis.

MATERIALS AND METHODS

We conducted a cross-sectional study with a control group of 85 women divided into 3 groups: group 1 consisted of 25 women without a history of nephrolithiasis, group 2 consisted of 35 women with only one episode of calcium nephrolithiasis, and group 3 consisted of 25 women with a history of recurrent calcium nephrolithiasis. Blood and urine biochemical study was performed, including markers related to lithiasis, and a bone mineral density study was done by use of bone densitometry.

RESULTS

Patients in group 3 showed statistically significantly elevated calciuria (15.4 mg/dL), fasting calcium/creatinine ratio (0.14), and 24-hour calcium/creatinine ratio (0.21) compared with groups 1 and 2. Moreover, this group of women with recurrent calcium nephrolithiasis had significantly elevated values of beta-crosslaps, a bone resorption marker, compared with groups 1 and 2 (p=0.000) and showed more bone mineral density loss than did these groups.

CONCLUSIONS

Recurrent calcium nephrolithiasis in women has a significant association with bone mineral density loss and with values of calciuria, both fasting and 24-hour.

摘要

目的

我们研究的目标是检测复发性钙肾结石女性患者血液和尿液中钙磷代谢及骨代谢的多项生化参数,以及骨密度。

材料与方法

我们进行了一项横断面研究,对照组为85名女性,分为3组:第1组由25名无肾结石病史的女性组成,第2组由35名仅有一次钙肾结石发作的女性组成,第3组由25名有复发性钙肾结石病史的女性组成。进行了血液和尿液生化研究,包括与结石形成相关的标志物,并通过骨密度测定法进行了骨密度研究。

结果

与第1组和第2组相比,第3组患者的尿钙(15.4毫克/分升)、空腹钙/肌酐比值(0.14)和24小时钙/肌酐比值(0.21)在统计学上显著升高。此外,与第1组和第2组相比,这组复发性钙肾结石女性的骨吸收标志物β-交联羧基末端肽值显著升高(p = 0.000),且骨密度损失比这两组更多。

结论

女性复发性钙肾结石与骨密度损失以及空腹和24小时尿钙值显著相关。

相似文献

1
Bone and metabolic markers in women with recurrent calcium stones.复发性钙结石女性的骨骼和代谢标志物
Korean J Urol. 2013 Mar;54(3):177-82. doi: 10.4111/kju.2013.54.3.177. Epub 2013 Mar 15.
2
Calcium renal lithiasis and bone mineral density. Importance of bone metabolism in urinary lithiasis.钙性肾结石与骨矿物质密度。骨代谢在尿路结石形成中的重要性。
Actas Urol Esp. 2013 Jun;37(6):362-7. doi: 10.1016/j.acuro.2012.10.003. Epub 2013 Feb 12.
3
Mineral density and bone remodelling markers in patients with calcium lithiasis.钙结石患者的骨密度和骨重建标志物。
BJU Int. 2011 Dec;108(11):1903-8; discussion 1908. doi: 10.1111/j.1464-410X.2011.10167.x. Epub 2011 May 9.
4
Osteopenia/osteoporosis in patients with calcium nephrolithiasis.钙结石患者的骨质减少/骨质疏松症
Urol Res. 2012 Dec;40(6):709-16. doi: 10.1007/s00240-012-0497-8. Epub 2012 Aug 12.
5
Association of severe calcium lithogenic activity and bone remodeling markers.严重钙结石形成活性与骨重塑标志物的关联。
Urology. 2013 Jul;82(1):16-21. doi: 10.1016/j.urology.2013.02.035. Epub 2013 Apr 16.
6
The importance of calciuria as lithogenic factors in patients with osteopenia/osteoporosis.在骨质减少/骨质疏松患者中,尿钙作为致石因素的重要性。
Int Urol Nephrol. 2015 Mar;47(3):445-9. doi: 10.1007/s11255-015-0918-z. Epub 2015 Feb 5.
7
Importance of citrate and the calcium : citrate ratio in patients with calcium renal lithiasis and severe lithogenesis.枸橼酸盐和钙:枸橼酸盐比值在钙性肾结石和严重结石形成患者中的重要性。
BJU Int. 2013 Apr;111(4):622-7. doi: 10.1111/j.1464-410X.2012.11292.x. Epub 2012 Jul 3.
8
Biochemical determinants of severe lithogenic activity in patients with idiopathic calcium nephrolithiasis.特发性钙肾结石患者严重成石活性的生化决定因素。
Urology. 2012 Jan;79(1):48-54. doi: 10.1016/j.urology.2011.07.1382. Epub 2011 Sep 9.
9
Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.氨基双膦酸盐和噻嗪类药物在伴有骨质减少/骨质疏松症、高钙尿症和复发性肾钙结石的患者中的作用。
Urology. 2013 Apr;81(4):731-7. doi: 10.1016/j.urology.2012.12.013. Epub 2013 Jan 30.
10
Treatment with hydrochlorothiazide and alendronate in patients with stones and bone mineral density loss. Evolution of bone metabolism and calciuria with medical treatment.氢氯噻嗪和阿仑膦酸钠治疗结石及骨密度降低患者。药物治疗对骨代谢和尿钙的影响。
Arch Esp Urol. 2016 Jan-Feb;69(1):9-18.

引用本文的文献

1
Bone resorption in dogs with calcium oxalate urolithiasis and idiopathic hypercalciuria.患有草酸钙尿石症和特发性高钙尿症的犬类的骨吸收
Res Vet Sci. 2019 Apr;123:129-134. doi: 10.1016/j.rvsc.2019.01.001. Epub 2019 Jan 4.
2
Low Colonization is Associated with Reduced Bone Mineral Density in Urinary Stone Forming Patients.低细菌定植与尿路结石形成患者骨密度降低有关。
Curr Urol. 2015 Dec;8(4):189-193. doi: 10.1159/000365715. Epub 2015 Nov 10.
3
Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis.肾结石、骨密度、骨质疏松症与骨折:一项系统评价和比较性荟萃分析
Osteoporos Int. 2016 Nov;27(11):3155-3164. doi: 10.1007/s00198-016-3658-8. Epub 2016 Jun 11.
4
The importance of urinary calcium in postmenopausal women with osteoporotic fracture.尿钙在绝经后骨质疏松性骨折女性中的重要性。
Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E183-6. doi: 10.5489/cuaj.2695.

本文引用的文献

1
Biochemical determinants of severe lithogenic activity in patients with idiopathic calcium nephrolithiasis.特发性钙肾结石患者严重成石活性的生化决定因素。
Urology. 2012 Jan;79(1):48-54. doi: 10.1016/j.urology.2011.07.1382. Epub 2011 Sep 9.
2
Metaphylaxis of urolithiasis.尿石症的预防
Arch Ital Urol Androl. 2009 Mar;81(1):32-9.
3
Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.阿仑膦酸钠与吲达帕胺单独或联合用于治疗与骨质疏松症相关的高钙尿症:两种药物和三种治疗方案的随机对照试验
Nephrol Dial Transplant. 2009 May;24(5):1472-7. doi: 10.1093/ndt/gfn690. Epub 2008 Dec 15.
4
A reference standard for the description of osteoporosis.骨质疏松症描述的参考标准。
Bone. 2008 Mar;42(3):467-75. doi: 10.1016/j.bone.2007.11.001. Epub 2007 Nov 17.
5
[The treatment of renal lithiasis with biphosphonates].[双膦酸盐治疗肾石病]
Arch Esp Urol. 2007 Sep;60(7):745-54. doi: 10.4321/s0004-06142007000700004.
6
Pathophysiology and clinical aspects of urinary lithiasis.尿石症的病理生理学与临床方面
Urol Int. 2007;79 Suppl 1:26-31. doi: 10.1159/000104438.
7
Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides.体外肾碎石术:噻嗪类药物治疗残余结石的进展
Urology. 2006 Nov;68(5):956-9. doi: 10.1016/j.urology.2006.06.007.
8
[Renal lithiasis. Biochemical changes in the follow-up].
Medicina (B Aires). 2006;66(3):201-5.
9
Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?监测骨质疏松症治疗:骨密度、骨转换标志物,还是两者兼用?
Am J Med. 2006 Apr;119(4 Suppl 1):S25-31. doi: 10.1016/j.amjmed.2005.12.020.
10
Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.骨转换生化标志物的早期变化可预测韩国绝经后骨质疏松妇女对抗吸收治疗的骨密度反应。
Endocr J. 2005 Dec;52(6):667-74. doi: 10.1507/endocrj.52.667.